Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Prednisone for LCH of Bone in Children
NCT06078969Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Nov 2023
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Langerhans cell histiocytosis (LCH) comparing Oral prednisone with Regular observation (2 arms). Primary endpoint: Progression-free survival at 2 years. Started Nov 2023; status: recruiting.
02
Drugs
prednisone
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT06078969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078969.